BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 6, 2015, Pages E536-E545

  Perna, Daniele ^a,b,h   Karreth, Florian A ^b,i   Rust, Alistair G ^a   Perez Mancera, Pedro A ^b   Rashid, Mamunur ^a   Iorioc, Francesco ^a,c   Alifrangis, Constantine ^a   Arends, Mark J ^d   Bosenberg, Marcus W ^e   Bollag, Gideon ^f   Tuveson, David A ^b,g   Adams, David J ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f PLEXXIKON INC   (United States)

^g Simons Center for Quantitative Biology   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

BRAF inhibitors; Drug resistance; Melanoma; Mouse models

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PROTEIN BAD; PROTEIN KINASE B; RAS PROTEIN; SCATTER FACTOR; AKT1 PROTEIN, MOUSE; B RAF KINASE; BAD PROTEIN, MOUSE; BRAF PROTEIN, MOUSE; ERAS PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN P21; SLEEPING BEAUTY TRANSPOSASE, HUMAN; SULFONAMIDE; TRANSPOSASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAF GENE; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOGENESIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; EMBRYO; ENZYME PHOSPHORYLATION; ERAS GENE; GENE; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN CELL; HYPERPIGMENTATION; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL LINE; MITF GENE; MOUSE; MOUSE MODEL; MUTAGENESIS; NONHUMAN; ONCOGENE; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; THYMOMA; TRANSPOSON; TUMOR REGRESSION; VIRUS ONCOGENE; ANIMAL; ANTAGONISTS AND INHIBITORS; DNA SEQUENCE; DRUG RESISTANCE; EMBRYONIC STEM CELL; EXOME; GENETIC ASSOCIATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING; TRANSGENIC ANIMAL; TUMOR CELL LINE; VALIDATION STUDY; WESTERN BLOTTING;

MURINAE; MUS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BCL-ASSOCIATED DEATH PROTEIN; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EMBRYONIC STEM CELLS; EXOME; GENETIC ASSOCIATION STUDIES; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MELANOMA; MICE; MUTAGENESIS; ONCOGENE PROTEIN P21(RAS); PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSPOSASES;

EID: 84922616437     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1418163112     Document Type: Article

References (66)

1. Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954.
2. Bollag G, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315):596-599.
3. Chapman PB, et al.; BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516.
4. Flaherty KT, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809-819.
5. Sosman JA, et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707-714.
6. Poulikakos PI, et al. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480(7377):387-390.
7. Shi H, et al. (2012) Melanoma whole-exome sequencing identifies (V600E)BRAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724.
8. Nazarian R, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326):973-977.
9. Emery CM, et al. (2009) MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106(48):20411-20416.
10. Whittaker SR, et al. (2013) A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 3(3):350-362.
11. Johannessen CM, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968-972.
12. Villanueva J, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18(6):683-695.
13. Wilson TR, et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487(7408):505-509.
14. Straussman R, et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487(7408):500-504.
15. Paraiso KH, et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71(7):2750-2760.
16. Haq R, et al. (2013) BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA 110(11): 4321-4326.
17. Ye Y, et al. (2013) Loss of PI(4,5)P2 5-phosphatase A contributes to resistance of human melanoma cells to RAF/MEK inhibitors. Transl Oncol 6(4):470-481.
18. Shao Y, Aplin AE (2010) Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70(16):6670-6681.
19. Hilmi C, et al. (2008) IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 128(6): 1499-1505.
20. Dankort D, et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5):544-552.
21. Dhomen N, et al. (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15(4):294-303.
22. Bosenberg M, et al. (2006) Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 44(5):262-267.
23. Wojnowski L, et al. (1997) Endothelial apoptosis in Braf-deficient mice. Nat Genet 16(3):293-297.
24. Pollock PM, et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33(1): 19-20.
25. Patton EE, et al. (2005) BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15(3):249-254.
26. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA (2005) Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436(7048):272-276.
27. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA (2005) Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436(7048):221-226.
28. Pérez-Mancera PA, et al.; Australian Pancreatic Cancer Genome Initiative (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486(7402):266-270.
29. Tsai J, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105(8):3041-3046.
30. de Ridder J, Uren A, Kool J, Reinders M, Wessels L (2006) Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLOS Comput Biol 2(12):e166.
31. van den Hurk K, et al. (2012) Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. Biochim Biophys Acta 1826(1):89-102.
32. Kamb A, et al. (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8(1):23-26.
33. Tsao H, Zhang X, Benoit E, Haluska FG (1998) Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16(26): 3397-3402.
34. Karreth FA, et al. (2011) In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147(2):382-395.
35. Garraway LA, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436(7047):117-122.
36. Johannessen CM, et al. (2013) A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504(7478):138-142.
37. Smith MP, et al. (2013) Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst 105(1):33-46.
38. Shi H, et al. (2014) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4(1):80-93.
39. Takahashi K, Mitsui K, Yamanaka S (2003) Role of ERas in promoting tumour-like properties in mouse embryonic stem cells. Nature 423(6939):541-545.
40. Liu Y, et al. (2013) Role of the ERas gene in gastric cancer cells. Oncol Rep 30(1):50-56.
41. Corcoran RB, et al. (2013) TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 5(196):196ra198.
42. Boisvert-Adamo K, Aplin AE (2008) Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 27(23):3301-3312.
43. Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE (2009) Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 7(4):549-556.
44. Datta SR, et al. (1997) Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell 91(2):231-241.
45. Bonni A, et al. (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286(5443): 1358-1362.
46. Fang X, et al. (1999) Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 18(48):6635-6640.
47. Scheid MP, Schubert KM, Duronio V (1999) Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J Biol Chem 274(43):31108-31113.
48. Tse C, et al. (2008) ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68(9):3421-3428.
49. Garnett MJ, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391):570-575.
50. Liu Y (1999) Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am J Physiol 277(4 Pt 2):F624-F633.
51. Kakazu A, Chandrasekher G, Bazan HE (2004) HGF protects corneal epithelial cells from apoptosis by the PI-3K/Akt-1/Bad- but not the ERK1/2-mediated signaling pathway. Invest Ophthalmol Vis Sci 45(10):3485-3492.
52. Lister JA, et al. (2014) A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo. J Invest Dermatol 134(1): 133-140.
53. Yokoyama S, et al. (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480(7375):99-103.
54. Hertzman Johansson C, et al. (2013) Association of MITF and other melanosomerelated proteins with chemoresistance in melanoma tumors and cell lines. Melanoma Res 23(5):360-365.
55. McGill GG, et al. (2002) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109(6):707-718.
56. Kubota E, et al. (2010) Role of ES cell-expressed Ras (ERas) in tumorigenicity of gastric cancer. Am J Pathol 177(2):955-963.
57. Aoyama M, Kataoka H, Kubota E, Tada T, Asai K (2010) Resistance to chemotherapeutic agents and promotion of transforming activity mediated by embryonic stem cell-expressed Ras (ERas) signal in neuroblastoma cells. Int J Oncol 37(4):1011-1016.
58. Kubota E, et al. (2011) ERas enhances resistance to CPT-11 in gastric cancer. Anticancer Res 31(10):3353-3360.
59. She QB, et al. (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8(4):287-297.
60. Cragg MS, et al. (2008) Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118(11): 3651-3659.
61. Sale MJ, Cook SJ (2013) The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Biochem J 450(2):285-294.
62. March HN, et al. (2011) Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 43(12):1202-1209.
63. Uren AG, et al. (2009) A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc 4(5):789-798.
64. Rashid M, Robles-Espinoza CD, Rust AG, Adams DJ (2013) Cake: A bioinformatics pipeline for the integrated analysis of somatic variants in cancer genomes. Bioinformatics 29(17):2208-2210.
65. Keane TM, et al. (2011) Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 477(7364):289-294.
66. Irizarry RA, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4(2):249-264.